This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomeAboutAboutBurden of IPDDosingDosingDosingAdministration and implementationEfficacy & SafetyEfficacy & SafetyEfficacySafety ProfileImmunogenicitySupport & OrderSupport & OrderEventsMaterialsVideosOrder Prevnar 13®AdherenceResources
Full Prescribing Information Indications Patient Site
Complete the Prevnar 13® 4-dose seriesBecause the threat of invasive pneumococcal disease (IPD) is still out thereWhen facing the serious threat of IPD ​​​​​​​​​​​​​​Are infants getting the 4 doses of Prevnar 13® that they need?

In infants and young children, Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) is administered as a 4-dose series at 2, 4, 6 and 12 to 15 months of age.1*†‡

 Learn more about dosing Loading

*The first dose may be given as early as 6 weeks of age.1
†The recommended dosing interval for the first, second and third doses is 4 to 8 weeks.1
‡The fourth dose should be administered at approximately 12 to 15 months of age and at least 2 months after the third dose.1

Model used for illustrative purposes only.

 What are the most common ways IPD can present in your practice?
 Find out Loading Impact of late doses
 Get the facts Loading Resources

Offer resources that may help improve adherence to the CDC-recommended vaccine schedule

 Look now Loading Order from Pfizer Prime

To stock Prevnar 13®, call
​​​​​​​1-800-666-7248 or click here

 Order now LoadingReferences:
Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) Prescribing Information, Wyeth Pharmaceuticals LLC, 2019.
Centers for Disease Control and Prevention. Pneumococcal Disease Surveillance and Reporting. https://www.cdc.gov/pneumococcal/surveillance.html. Updated September 6, 2017. Accessed October 27, 2019.

PREVNAR 13® is a registered trademark of Wyeth LLC.
Manufactured by Wyeth Pharmaceuticals Inc.
© 2022 Pfizer Inc.

 

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2022 Pfizer Inc. All rights reserved.

PP-PRV-USA-0180
You are now leaving Pfizer
You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 

PP-PRV-USA-0144
INDICATION AND LIMITATIONS OF USE
  • Prevnar 13® is a vaccine indicated for active immunization for the prevention of disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F​​​​​​​​​​​​​​
  • In children 6 weeks through 17 years for invasive disease caused by the 13 serotypes, and for children 6 weeks through 5 years of age for otitis media caused by 7 of the 13 serotypes only (4, 6B, 9V, 14, 18C, 19F, and 23F)
Limitations of Use and Effectiveness
  • Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine
IMPORTANT SAFETY INFORMATIONIndications
  • Severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 13® or any diphtheria toxoid–containing vaccine is a contraindication
  • Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant's medical status, and the potential benefits and risks
  • In infants and toddlers, the most commonly reported serious adverse events were bronchiolitis (0.9%), gastroenteritis (0.9%), and pneumonia (0.9%)
  • In children 6 weeks through 17 years, the most commonly reported solicited adverse reactions were injection site tenderness, redness, or swelling, irritability, decreased appetite, decreased or increased sleep, and fever
  • In children 6 years through 17 years of age, Prevnar 13® is administered as a single dose
Patients should always ask their doctors for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). ​​Visit www.vaers.hhs.gov or call 1-800-822-7967.Please see full Prescribing Information for Prevnar 13®.
  • Prevnar 13® is a vaccine indicated for active immunization for the prevention of disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F​​​​​​​
  • In children 6 weeks through 17 years for invasive disease caused by the 13 serotypes, and for children 6 weeks through 5 years of age for otitis media caused by 7 of the 13 serotypes only (4, 6B, 9V, 14, 18C, 19F, and 23F)​​​​​​​
​​​​​​​​​​​​​Limitations of Use and Effectiveness
  • Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine

Please see full Prescribing Information.

OK. We'll need you to sign in before we can determine if you are aligned with a sales representative. 

If you select 'Yes', you will be required to enter your username and password in the sign-in form that will appear over this window.

Would you like to sign in now?